FOLD News and Press, Amicus Therapeutics Inc. From 04/15/19

CRANBURY, N.J., April 15, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the company will present initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Pompe disease in a poster at the American Society of Gene ...

AVROBIO (NASDAQ: AVRO ) initiated with Buy rating at Janney Montgomery Scott. More news on: AVROBIO, Inc., Amicus Therapeutics, Inc., Celgene Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

The USPTO has issued  two new patents to Amicus Therapeutics (NASDAQ: FOLD ) directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, to enhance uptake. ...

CRANBURY, N.J., March 20, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the United States Patent and Trademark Office has issued two new patents directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-gluco...

Amicus Therapeutics, Inc. (FOLD) Q4 2018 Results Earnings Conference Call February 28, 2019, 08:30 AM ET Company Participants Sara Pellegrino - Vice President of Investor Relations and Corporate Communication John Crowley - Chairman and Chief Executive Officer Bradley Campbell - ...

Amicus Therapeutics ( FOLD +2.5% ) FY results : Revenues: $91.2M (+147.2%). More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary Read more ...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2018 Q4 earnings Read more ...

Amicus Therapeutics (NASDAQ: FOLD ): FY GAAP EPS of -$1.88. More news on: Amicus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Continued Strong Galafold Launch Trends in Early 2019 - On Track to Achieve FY19 Revenue Guidance of $160M-$180M FY18 Galafold Revenue of $91.2M Reflects 650+ Fabry Patients Treated at end of 2018 - 1,000+ Patients Expected by end of 2019 Clinical Data Out to Month 24 and Bre...

AAON , ABB , ACIW , AKRX , AMCX , AMRX , BCPC , BID , BMCH , BPMP , BUD , CARS , CM , CMD , CNP , CROX , CWEN , CWT , DAVA , DEA , EGRX , ENDP , EXLS , FOLD , FRO , FSS , GOLF , GTN , GTT , HMHC , HRI , IBP , ICPT , IRDM , JCP , JD , KDP , LAUR , LKQ ,...